Department of Pathology and Laboratory Medicine and Henry Ford Cancer Institute, Henry Ford Health System, Detroit, MI, USA.
Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI, USA.
Histopathology. 2018 Oct;73(4):681-691. doi: 10.1111/his.13672. Epub 2018 Aug 6.
Pathological staging of renal cell carcinoma (RCC) can be challenging compared to other cancer types, as invasion often manifests as finger-like protrusions into vascular spaces or renal sinus tissue. Although prior studies have shown larger tumour size to be correlated highly with renal sinus invasion, prospective data on evaluating pathological stage are limited. We evaluated a large series reported by one urological pathologist.
Three hundred consecutive specimens were reviewed. Tumours larger than 5 cm were routinely sampled extensively or grossly re-reviewed when no extrarenal extension was identified on initial examination. Apparent multifocal disease was assessed critically for intravascular spread. Retrograde venous invasion was reported in 15 of 300 (5%) cases, 13 of 15 of which were clear cell RCC. Of a total of 163 specimens with clear cell histology, only five of 34 (15%) tumours 7 cm or larger were reported as pT2, all of which had an explanatory comment indicating the absence of definitive extrarenal spread. In contrast, 15 of 20 (75%) pT2 tumours were non-clear cell histology (papillary, chromophobe and translocation-associated). Comparing pT3a or higher tumours, the median tumour size in cases with retrograde venous invasion was 8.0 cm, compared to 6.2 cm in cases without retrograde venous invasion (P = 0.005).
Our findings support that retrograde venous invasion should be considered carefully before diagnosing multifocal clear cell RCC, which is rare in the sporadic setting. In the absence of vascular invasion, multifocal clear cell papillary RCC can be a mimic. pT2 occurs more frequently with non-clear cell histology (particularly papillary or chromophobe RCC).
与其他类型的癌症相比,肾细胞癌(RCC)的病理分期可能具有挑战性,因为浸润通常表现为血管空间或肾窦组织中的指状突起。尽管先前的研究表明肿瘤较大与肾窦侵犯高度相关,但评估病理分期的前瞻性数据有限。我们评估了一位泌尿科病理学家报告的大量系列病例。
共回顾了 300 例连续标本。当在初次检查时未发现肾外延伸时,常规广泛采样或重新检查大于 5cm 的肿瘤。对明显的多灶性疾病进行了仔细评估,以确定是否存在血管内扩散。报告了 300 例病例中有 15 例(5%)存在逆行静脉侵犯,其中 13 例为透明细胞 RCC。在总共 163 例具有透明细胞组织学的标本中,仅 5 例(15%)大小为 7cm 或更大的肿瘤被报告为 pT2,所有这些肿瘤都有明确的解释性评论,表明没有明确的肾外扩散。相比之下,20 例(75%)pT2 肿瘤为非透明细胞组织学(乳头状、嫌色细胞和易位相关)。比较逆行静脉侵犯的 pT3a 或更高肿瘤,逆行静脉侵犯病例的肿瘤中位大小为 8.0cm,而无逆行静脉侵犯病例的肿瘤中位大小为 6.2cm(P=0.005)。
我们的研究结果支持在诊断罕见的散发性多灶性透明细胞 RCC 之前应仔细考虑逆行静脉侵犯。在没有血管侵犯的情况下,多灶性透明细胞乳头状 RCC 可能是一种模拟。非透明细胞组织学(特别是乳头状或嫌色细胞 RCC)更常发生 pT2。